Targeting Rac1 to treat medulloblastoma in children
Rac1 Inhibition for the treatment of medulloblastoma
This study is testing a new drug called GYS32661 to see if it can help treat medulloblastoma, a type of brain cancer in kids, by blocking a protein that helps cancer cells grow.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10995293 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for medulloblastoma, a type of brain cancer that primarily affects children. The study focuses on inhibiting a protein called Rac1, which is involved in cancer cell growth and signaling. Researchers will use a specially developed drug, GYS32661, to see if it can reduce the activity of key signaling pathways that contribute to tumor growth. The research includes both laboratory tests and animal models to evaluate the effectiveness of this treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with medulloblastoma, particularly those who have not responded well to traditional therapies.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with medulloblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel therapy that improves outcomes for children with medulloblastoma and reduces the side effects associated with current treatments.
How similar studies have performed: While targeting Rac1 in cancer treatment is a novel approach, there have been successful studies targeting similar pathways in other cancers, suggesting potential for success in this area.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Ayad, Nagi G — Georgetown University
- Study coordinator: Ayad, Nagi G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.